Pacific Edge, which is banking on successfully commercialising its Cxbladder urine testing product, widened its first-half loss as it ramps up spending to set up its business in the US.
The Dunedin-based company made a loss of $3.2 million, or 1.2 cents per share, in the six months ended September 30, from $1.7 million, or 0.9 cents, a year earlier, it says in a statement.
Revenue climbed 29% to $325,000, though just $11,000 of that came from external customers.
"The majority of this net loss is the investment in the company's setting up of business in the US, clinical trials, product development and intellectual property as it is expensed," it says.
"The company is investing significant funds in the set-up and running of the commercial laboratory and the development of the US strategy in this financial year."
The shares fell 2.2% to 44 cents, having surged 137% this year. That values the company at $122.7 million.
Pacific Edge hopes to successfully bring its urine sampling system to market, having won clinical confirmation the Cxbladder is at least as effective as other methods from the American Journal of Urology.
The local company says that could be worth up to $100 million in five years.
Last month, the company completed its US lab in Pennsylvania and is waiting on regulatory approval to use the building.
This article is tagged with the following keywords. Find out more about MyNBR Tags
- PM right to speak out on NZ Super Fund CEO pay, shareholders group says
- Chris Liddell divesting himself of Xero shares, options
- Political activist Nicky Hager takes next step in privacy case against Westpac
- General Cable's headquarters up for sale
- TVNZ first-half earnings drop as ad revenue falls faster than expenses
Most listened to
- Sky TV boss John Fellet says he's happy to sign a contract with Spark
- NZ Shareholders Association chairman John Hawkins says all shareholders should question rising executive pay
- Snowball Effect has appointed former Russell McVeagh lawyer and technology marketer Peter Thomson as Head of Digital
- Hobson Wealth’s James Grigor on how Air NZ can deal to competition
- Westpac's Sarah Drought says the usually dry Summer months have feared will for dairy farmers, due to a wet Spring